ARCHIVES

DeVita’s “Radical” Statement – Resectability Rate Should Be The Cure Rate

This article is from The Cancer Letter archive.

Vol. 02 No. 40 | October 1, 1976

Download PDF Visit The Full Archive

Related Articles

An Earmark In The Making? NCI Urged to Boost Gastric Cancer Funding

December 17, 2013

ASCO Strategic Plan Seeks To Increase Value to Members, Public

May 24, 2002

Congress Passes NIH Reauthorization.

December 15, 2006

FDA Approves Gilotrif Tablets in NSCLC, Boehringer Ingelheim’s First Approved Cancer Drug

July 26, 2013

Conversation with The Cancer Letter: Kazerooni: The Case for Broad Coverage

March 21, 2014

Major Changes In NCI Drug screening Tumor Panels Approved

June 18, 1982